Intellia Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
NTLA$11.17-7.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(Amounts in thousands, except share data)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common · Paid-In · Comprehensive · Accumulated · Stockholders’ | ||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance at December 31, 2021 | 74,485,883 | $7 | $1,745,870 | $(2,632) | $(703,001) | $1,040,244 |
| Issuance of common stock through follow-on offerings, net of issuance costs of $253 | 7,532,751 | 1 | 337,891 | - | - | 337,892 |
| Issuance of common stock through at-the-market offerings, net of issuance costs of $164 - 2019 Sale Agreement | 579,788 | 1 | 38,885 | - | - | 38,886 |
| Issuance of common stock through at-the-market offerings, net of issuance costs of $125 - 2022 Sale Agreement | 3,395,339 | - | 189,011 | - | - | 189,011 |
| Exercise of stock options | 883,954 | - | 14,517 | - | - | 14,517 |
| Vesting of restricted stock units | 147,674 | - | - | - | - | - |
| Issuance of shares under employee stock purchase plan | 77,618 | - | 2,649 | - | - | 2,649 |
| Stock-based compensation | - | - | 91,400 | - | - | 91,400 |
| Other comprehensive income (loss) - unrealized loss on marketable securities | - | - | - | (1,637) | - | (1,637) |
| Other comprehensive income (loss) - unrealized loss on equity method investment | - | - | - | (3,192) | - | (3,192) |
| Net loss | - | - | - | - | (474,186) | (474,186) |
| Balance at December 31, 2022 | 87,103,007 | 9 | 2,420,223 | (7,461) | (1,177,187) | 1,235,584 |
| Issuance of common stock through at-the-market offerings, net of issuance costs of $376 - 2022 Sale Agreement | 4,122,824 | - | 121,870 | - | - | 121,870 |
| Contingent consideration paid to Rewrite Holders | 567,045 | - | 24,126 | - | - | 24,126 |
| Exercise of stock options | 385,130 | - | 6,599 | - | - | 6,599 |
| Vesting of restricted stock units | 677,055 | - | - | - | - | - |
| Issuance of shares under employee stock purchase plan | 142,097 | - | 3,929 | - | - | 3,929 |
| Stock-based compensation | - | - | 134,050 | - | - | 134,050 |
| Other comprehensive income (loss) - unrealized gain on marketable securities | - | - | - | 3,635 | - | 3,635 |
| Other comprehensive income (loss) - unrealized gain on equity method investment | - | - | - | 1,568 | - | 1,568 |
| Net loss | - | - | - | - | (481,192) | (481,192) |
| Balance at December 31, 2023 | 92,997,158 | 9 | 2,710,797 | (2,258) | (1,658,379) | 1,050,169 |
| Issuance of common stock through at-the-market offerings, net of issuance costs of $254 - 2022 Sale Agreement | 7,004,370 | 1 | 174,823 | - | - | 174,824 |
| Exercise of stock options | 373,807 | - | 5,862 | - | - | 5,862 |
| Vesting of restricted stock units | 1,433,669 | - | - | - | - | - |
| Issuance of shares under employee stock purchase plan | 220,590 | - | 2,986 | - | - | 2,986 |
| Stock-based compensation | - | - | 154,273 | - | - | 154,273 |
| Other comprehensive income (loss) - unrealized gain on marketable securities | - | - | - | 731 | - | 731 |
| Reclassification of other comprehensive income (loss) - equity method investment | - | - | - | 2,132 | - | 2,132 |
| Net loss | - | - | - | - | (519,021) | (519,021) |
| Balance at December 31, 2024 | 102,029,594 | $10 | $3,048,741 | $605 | $(2,177,400) | $871,956 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.